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An overview on targeted personalized medicine is given describing the developments in Japan of lung cancer patients. These
new targeted therapies with novel personalized medicine drugs require new implementations, in order to follow and monitor
drug eﬃcacy and outcome. Examples from IRESSA (Geﬁtinib) and TARCEVA (Erlotinib) treatments used in medication of lung
cancer patients are presented. Lung cancer is one of the most common causes of cancer mortality in the world. The importance
of both the quantiﬁcation of disease progression, where diagnostic-related biomarkers are being implemented, in addition to
the actual measurement of disease-speciﬁc mechanisms relating to pathway signalling activation of disease-progressive protein
targets is summarised. An outline is also presented, describing changes and adaptations in Japan, meeting the rising costs and
challenges. Today, urgent implementation of programs to address these needs has led to a rebuilding of the entire approach of
medical evaluation and clinical care.
1.HealthCareCosts andImpact
The rising cost in Japanese healthcare system, with an elderly
population that is expected to reach 30% of the population
by2020,isamajorchallengetothehealthcaresystem(http://
www.ipss.go.jp/syoushika/tohkei/Popular/Popular2011.asp?
chap=0 in Japanese). This growth of elderly population in
society is a trend that can be seen in other countries as well.
The US, for instance, has an estimated growth of 16%, and
Germany 23% by 2020. However, the Japanese situation
is extreme in that 39.6% is predicted by 2050, which is
far more than any other country in the world [1]. At the
moment, Japan has most probably the largest future costs
associated to the increasing elderly population. At the same
time, the country has one of the lowest medical health
care spends (in comparison to other developed countries)
which is about 8.1%. This part of the budget is used on the
national medical expense, based on the national GDP. These
anticipated future costs and changes in society would be
challenging the Japanese society for decades to come. To
meet these alterations, it is envisioned that major changes
will be implemented in emerging technologies and patient
treatment procedures [2].
It is clear from a historical background that the future
of biomedical sciences will be driven by the ability to adopt
novel technologies, which will generate huge amounts of
data outputs from clinical samples. One major consequence
will be to utilize the new technology deliveries as the basis
to understand the disease complexity and to develop new
treatments. This is especially relevant to diseases such as lung
cancer (LCa) and chronic obstructive pulmonary disease
(COPD), the latter, a disease that is rapidly increasing
and that presents itself in combination with LCa. These
pulmonary diseases currently carry a huge mortality and2 International Journal of Proteomics
cost to the health care system. At the same time, these
diseases have been shown to advance prognosis and reduced
cost to healthcare system by early detection, prescription
of personalized medicine, and evaluation of response to
treatment. These diseases are known to be highly complex
and multifactorial. It is not possible at this stage to assign a
single molecule related to one disease or clinical complaint.
On the contrary, there are hundreds (multiple signals), and
there is a need of selecting from multiple signals. This
is a highly demanding task, as this is hampered by the
lack of tools and data for early diagnosis. In addition,
modeling of disease progression and evaluation of treatment
response is also something that the science community is
still working on, and not a scientiﬁc tool that is available.
LCa and COPD are both known to cluster in families and
are more common in elderly population. Aggregation has
been observed in families which would suggest a genetic
or an environmental connection. Pathologically it has been
observedthatalowerlungfunctionisseeninCOPDpatients,
which would indicate a signiﬁcant risk and a valuable
predictor of incidents in lung cancer. We are experiencing
that prevalence is increasing in patients with lung cancer,
which is independent of age, sex, and smoking history.
Consequently, there is a sixfold higher prevalence in lung
cancer patients.
Currently, these disease areas are facing major challenges
where major research resources are directed, such as the
stratiﬁcation of phenotypes along with an early indication of
disease and diagnostics that can identify disease appearance
and staging. With an optimal treatment, based on individual
medical needs, is currently fundamental to the rebuilding
of the entire medical and clinical system. This will be
including the cases of lung tumors, their diagnosis, the
surgical treatments, and/or chemotherapy of each individual
subject.
In this respect, the concept of personalized medicine
declared as a working proposition still is in its initial phase
of developments and implementation worldwide. A major
and unremitting eﬀort is considered necessary to achieve
these developments such as the requirement to establish
the ranges of quantitative assays. These assays need to
be able to separate healthy from diseased individuals in
a variety of basic sciences such as genomics, proteomics,
and metabolomics, as well as clinical sciences. Clinically,
surveillance, diagnosis, and treatment should be in focus,
whichthenisappliedtomatchscenariosofindividualdisease
with best practice individual treatment eﬃcacy. Lately, a
major focus of the introduction of targeted personalized
medicine is marker associations to drug eﬃcacy and safety.
The targeted treatments are reducing costs for an aging
Japanese population.
2. Cost andBeneﬁts for the Japanese Patients
In many respects, Japan has been pioneering the optimal
use of drugs for the Japanese population. This is especially
highlighted by the successful use of personalized medicines
f o rl u n gc a n c e rt r e a t m e n t s .T h ee p i d e r m a lg r o w t hf a c t o r
receptor (EGFR) tyrosine kinase inhibitors (TKIs) are by
now well-established treatment for advanced non-small-
cell lung cancer (NSCLC). The advantage with these new
generation of targeted drugs is that they in comparison to
chemotherapy show that they are typically well tolerated
and without cytotoxic side eﬀects. The discovery of a novel
class of epidermal growth factor receptor-tyrosine kinase
inhibitors (EGFR-TKIs) was ﬁrst made by AstraZeneca in
1994. EGFR is a target that is overexpressed in high levels on
cancer cell surfaces in general, and particularly on non-small
cell lung cancer (NSCLC) cells. Consequently, elevated levels
of EGFR have been linked with progressed disease, cancer
spread, and poor clinical prognosis. The tyrosine kinase
enzyme(s) in the EGF receptor is inhibited by Geﬁtinib [3].
It results in a blocking eﬀect of signaling that is linked to the
functions of growth and spread of tumors. These types of
tumors are predominantly eﬀective with IRESSA treatments.
The speciﬁc action of Geﬁtinib is linked to a high-aﬃnity
binding to the mutated EGFR tyrosine kinase domain with
high speciﬁcity. A signiﬁcant tumor shrinkage upon IRESSA
treatment occurs in the majority of patients with EGFR
mutation.
In this respect, both IRESSA (Geﬁtinib) and TARCEVA
(Erlotinib)havebeenusedbyJapanesepatientsbetween2002
and2007,respectively,fortreatmentofadvancedNSCLC[4].
AstraZeneca was the ﬁrst pharma company that managed to
get the targeted TKI, small molecule drugs to eﬃciently treat
lung cancer patients. The chemical properties of Erlotinib
and Geﬁtinib drug compounds are somewhat similar, while
the chemical structures vary signiﬁcantly, as shown in
Figure 1.
These targeted small molecule drugs are used as oral
monotherapy treatments. They have been proven to oﬀer a
superiorqualityoflifecomparedwithdoubletchemotherapy
(carboplatin/paclitaxel) as ﬁrst-line treatment for EGFR
mutation-positive advanced NSCLC. The personalized ther-
apy approach was also recently proven to be applicable, not
only to Japan, but also to Asians in general.
In Japan, rising costs have impacted on the framework
of maintaining an eﬃcient and eﬀective healthcare system.
Today, urgent implementation of programs to address this
needhasledtoarebuilding oftheentire approachofmedical
evaluationandclinicalcare.Centraltothisrealignmentisthe
concept and practice of providing personalized medicine as
an eﬀective means for delivering eﬀective care.
Currently, there are some reports on the costs involved
in patient treatments utilizing patient diagnosis upon drug
use that ultimately relate to the issue of responders versus
nonresponders. This is an important consideration that gets
more and more attention since the overall economy, that
societyneedstoprovide,isrelatedtothecostsofpersonalized
medicines, which in most cases are signiﬁcantly higher than
many other traditional drugs. Davis et al. recently presented
new developments and experiences that increasingly conﬁrm
the value of using personalized medicines [5]. From this
paper, it has been concluded that protein- and genetic-
biomarker diagnosis show increasingly high cost-eﬀectivity,
inprovidingtherightmedicinetotherightpatientattheﬁrst
prescription. Recent medical savings was reported, whereInternational Journal of Proteomics 3
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Figure 1: Chemical drug structure of Geﬁtinib, as a freebase (a) and Erlotinib as a (HCl) salt (b), respectively.
$40–80,000/year and patient is saved by the introduction of
personalized medicine [5]. Safety considerations regarding
p o s s i b l es i d ee ﬀects are also an added value, when patients
show a negative drug test [6, 7].
As Japan currently is the world’s largest market for
tobacco products, consequently smoking related lung can-
cer’s mortality has already been the highest among all
cancers.Theselifeconditionswillhaveasevereimpactonthe
quality of life of the smoke-induced and -related diseases in
Japan. These eﬀects are probably higher in Japan than in any
other country, although the situation in China is alarming
as well. In China, the combination of smoking, organic
cooking, and the environmental factors are key drivers of
lung cancer and COPD.
The tough challenge that the physician is faced with is to
treat with an eﬀective drug, and examples of these challenges
have been reported and presented on at international
congresses by our group over the years. The lung cancer
phenotype is also of mandatory importance to correctly
diagnose the cancer variant. Standard computer tomography
(CT) imaging could eﬃciently be complemented by protein
biomarker assays, such as multiplexing multiple reaction
monitoring (MRM) assays [8, 9]. In addition, a multicenter
study recently presented the solidity of the MRM technology
platform [10].
Looking into the pipeline of coming drug products,
currently in clinical phase trials, the expectation of new,
targetedmedicines,aswellasantibody-basedbiopharmaceu-
ticals, is expected to grow considerably. Biopharmaceutical
medication such as in the treatment of NSCLC patients
[11] revealed that Bevacizumab, a monoclonal antibody
against vascular endothelial growth factor, has been shown
to beneﬁt patients with non-small-cell lung cancer resulting
in a signiﬁcant survival beneﬁt [12].
The total market of targeted anticancer drugs in Japan,
Europe, and United States has been continuously increas-
ing which exceeded more than US$28 billion. Especially,
regarding antibody drugs, their size in 2007 was around
US$36 billion and estimated to increase up to US$67
billion in 2013. In Japan, about 10 antibody drugs were
currently in market, which cover a total of 1 billion US$
(http://www.seedplanning.co.jp/press/2008/0610.html).
PersonalizeddrugshaveanaturalYing&Yangpartnering
eﬀect within the treatment concept, which is the diagnostic
marker that can assign an optimal drug treatment strategy
that will beneﬁt both the patient as well as the taxpayers.
The future optimal concept that healthcare institutions
as well as politicians and industry are looking for is the
following:
“The Right Medicine to The Right Patient at the
Right Time Point.”
3.ImpacttoSocietyof PersonalizedMedicines
Genetic alterations of EGFR (exons 18, 19, 20, and 21)
are important for predicting the eﬃcacy of personalized
medicine such as IRESSA in patients with lung cancer [13,
14].
The observation of EGFR somatic mutations in Japanese
patients was made at a time point during the phase III study
with IRESSA in North America [15]. The phase III study was
not able to show a statistical signiﬁcance of the drug with the
criteria that were set at the time. However, previously, in the
phase II study, the study outcome was highly successful with
the dose and conditions given at the time, why AstraZeneca
was urged to start production and distribution to patients
before the phase III study was ﬁnalized. This was also the
action that AstraZeneca took at the time. Nonetheless, at
this stage, the subset of the Asian part of the patient cohort
did prove a signiﬁcant outcome upon IRESSA treatment,
why the mode-of-drug action already at this time point was
suspectedtoberelatedtoEGFRmutation.Thetesttoanalyze
the EGFR mutation status was developed that could identify
one phenotype: mutated versus nonmutated [13]. These
ﬁndings were associated with a long path of mechanistic
development works. The resulting data from these studies
and additional followup investigations resulted in a standard
procedure using the EGFR-mutation assay, which could
detect mutations in exon18 (G719A/C/S), exon19 (E746-
A750 deletion, L747-P753 deletion insertion S), exon20
(S768I),andexon21(L858I,L861Q)morethan1%mutation
rate in the clinic today. In Japan, a positive indication will
result in personalized medicine prescriptions [13, 16].
In protein expression research today, we discover,
develop, and validate proteomics ﬁndings for new prospect
applications in a clinical setting. As there is increasing
funding globally available for research programs that can4 International Journal of Proteomics
improve the diagnosis and stratiﬁcation of patients, as well
as biomarkers for both safety assessments and eﬃcacy, an
increasing number of studies and study data that illustrate
these developments are being published, as outlined in
Figure 2.
Geﬁtinib (IRESSA, ZD1839) was developed as a speciﬁc
inhibitor of the EGFR tyrosine kinase. Geﬁtinib targets
the EGFR for therapeutic drug intervention within lung
cancer. Early reports appeared on the experience of lung
cancer patients with EGFR mutations. These were among
the ﬁrst clinical data that provided correlation with clinical
response to Geﬁtinib therapy [16]. Personalized medicines
have an improved eﬃcacy over chemotherapy and radiation
treatments. While targeted drugs can reach 70–75% eﬃcacy,
the combined eﬀects of LCa chemotherapy and radiation
will reach about 35%. With respect to the well-being of
patients, the targeted drugs are not only more eﬃcient but
also provide an improvement in quality of life.
Recently a clinical study in four Asian countries was
conducted:theIRESSAPan-AsiaStudy,the“IPASS”study,in
which 1,217 NSCLC patients were enrolled [17]. The IPASS
study was an open label, randomised, parallel-group study
that assessed the eﬃcacy, safety, and tolerability of IRESSA
versus doublet chemotherapy (carboplatin/paclitaxel) as
ﬁrst-line treatment in a clinically selected population of
patients from Asia.
The adenocarcinoma cohort of the study with Japanese
patients was enrolled for eﬃcacy biomarker discovery. The
ultimate objective is to identify responders to Geﬁtinib treat-
ment to nonresponders. The ﬁnal outcome for diagnostic
prediction is still under investigation.
4.ClinicalBiomarkers
There is a lack of protein biomarker and imaging diagnostics
today within lung disorders, such as LCa and COPD.
These new clinical tools are expected to be used as early
indicator of disease, or as personalized indicator assays for
targeted and stratiﬁed disease phenotype drug treatments
in the near future. There is also a poor understanding of
the mode of drug action mechanisms, by commonly used
therapies, which is also true for new drugs introduced to
the market. The actual targeted cells and proteins within
disease and the actual drug interactions are by no means
understood for most medicines used in today’s therapies.
These drug characteristics are needed for both eﬃcacy
and safety improvements and also requested by regulatory
authorities, like FDA, MLHW, and EMEA.
Using a multiple biomarker approach such as proteomics
(the simultaneous study of large parts of the human pro-
t e o m et og i v eag l o b a lv i e wo fd i ﬀerential expression of pro-
teins in blood or tissue), rather than simply a conventional
single biomarker, potentially increases predictive power
both through increased robustness deriving from multiple
measurements and the opportunity to combine information
from multiple biological processes. To support high-quality
generation of such information, we combined in a novel
way several key study components: robust study design,
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Figure 2: Publication frequency during the past 10 years using the
keyword “clinical biomarker” in search of ISI Web of Knowledge on
April 29, 2011.
well-deﬁned phenotypic deﬁnitions, careful sample collec-
tion procedures, stable advanced liquid-chromatography
(LC-) tandem mass spectrometry, MS/MS-based peptide
separation and detection methods, and statistical analysis
incorporating proteomic and clinical information. We devel-
oped stringent methods for database protein annotation
of detected peptide peaks and biological interpretation
using literature mining software, plus extensive quality
control and validation in lung cancer studies. The ﬁrst
presentation on IRESSA biomarkers was presented at the
European Cancer meeting (ECCO, Paris, France) in 2007
(http://www.ncbi.nlm.nih.gov/pubmed/16381621).
It is also expected that clinical chemistry diagnosis
with biomarkers will become highly valuable as a screening
platform with speedy and cheap diagnosis assays in relation
to imaging, where, for instance, a typical pricing for CT or
magnetic resonance imaging (MRI) in Japan is in the order
of $10,000.
Mass-spectrometry-based proteomic approaches are
based on digital molecular recognition (m/z, mass over
charge) and sequencing in high resolution, and so those
investigations of lung cancer have thrown light on under-
standing complexity of patient disease status, and from
the clinicians’ point of view, we believe that a utilization
of useful biomarkers based on their quantitative molec-
ular expressions can stratify patients and improve their
therapeutic strategies for better clinical outcomes, and
that such approaches would diminish unnecessary multiple
treatments, which shall contribute to reduction of medical
healthcare costs.
As the ﬁrst country in the world, Japan has declared a
pricing strategy that includes demands for biomarker diag-
nostics that should be used in combination with new drugs
introduced into the market [18, 19]. Thereby, a targeted
treatment with patient stratiﬁcation will be achieved, with
phenotype selection for responders to drug treatment [20].
In this declaration, pharmacogenomic and proteomic
technologies are promoted in the discovery and devel-
opment of drug-related biomarkers by the drug pric-
ing committee within the MHLW (http://www.mhlw.go.jp/
shingi/2009/07/dl/s0715-9a.239.pdf).International Journal of Proteomics 5
The overall aim of this declaration is to reach a Japanese
pricing strategy that will be used in order to promote safe
and eﬃcient approved drugs for the treatment of Japanese
patients.
4.1. Drug Safety Biomarker Studies. Stratiﬁcation of patients
who will beneﬁt from Geﬁtinib treatment or even suﬀer
side eﬀects is major medical concern. A large Geﬁtinib
postmarketing surveillance study in Japan (3,322 patients)
reported 5.8% in rate of intestinal-lung-disease-(ILD-) type
events. To reveal risk factors of ILD occurrence, a large-scale
plasma proteomic study has been conducted in a cohort of
NSCLC patients treated with Geﬁtinib [18, 19].
Reports have been coming from Japanese patients with
non-small-celllungcancer,treatedwithGeﬁtinib,thatevents
of ILD appear some weeks after ﬁrst administration of drug.
ILD is a highly heterogeneous pathophysiology state that is
not easily diagnosed.
I L Dw i l la ﬀect the lung parenchyma and/or the alveolar
region [21–23]. It was also presented by Kudoh’s group that
a high prevalence of drug-induced pneumonia in Japan has
been identiﬁed in several studies [24–27]. Speciﬁc Geﬁtinib-
related ILD occurrence has also been reported in a number
of studies, where the occurrence frequency and predictive
factors have been investigated [24–27].
A number of reports have been made over the last
4 years, where Geﬁtinib treated patients developing ILD
were compared to a control group where the patients
did not develop ILD [18]. In 2009, preliminary data
w e r ep r e s e n t e do ns a f e t yb i o m a r k e r sa tt h eE u r o p e a n
ProteomicsAssociationCongress(Stockholm,Sweden)from
Japanese lung cancerpatients undergoing IRESSA treatment.
(http://www.eupa.org/EuPA2009/proceedings/6.Posters/2.%
20Biomarker%20Proteomics%20and%20Applications%20
%2874%29/P2-43.pdf).
The biomarker candidates were presented for the ﬁrst
time at the 26th ISPE Congress (International Conference on
Pharmacoepidemiology and Therapeutic Risk Management)
in 2010 in Brighton, UK (http://www.pharmacoepi.org/
meetings/26thconf/26th ICPE Final Program.pdf).
Recent followup patient analysis with plasma samples
from the respective patient groups (CASES and CONTROLS
of ILD) was analyzed by shotgun sequencing, utilizing
the LC-MS proteomics platform [28, 29]. Typically, tens
of thousands of mass signals generated from expressed
protein sequences were detected, from where the diﬀerential
expression analysis was performed. In parts of these studies,
there was like ∼7 million sequence data generated, with
MS/MS fragmentations [30]. This is probably the largest
clinical protein biomarker discovery study ever performed in
the industry where personalized medicine treatments were
made. The resulting outcome, in terms of protein sequence
output and the clinical data within the IRESSA repository
database, must also be one of the largest ever undertaken
[30]. The future targeted drug treatments inking eﬃcacy
with safety was pioneered in Japan, and the improved quality
of life for patients in addition to the cost beneﬁt society will
gain is illustrated in Figure 3.
Patients
Healthcare
clinic CT
Diagnosis:
emphysema
Drug 
treatment
Optimized personalized medicine:
responder
No side effects
Test:
Blood
++ +/− eﬃcacy
+/− safety
Figure 3: Diagnostic testing linked to targeted personalized drug
treatment of lung cancer patients.
4.2. Speciﬁc Lung Cancer Phenotype Markers. Proteomic
investigations of lung cancer use clinical materials such as
frozen and formalin-ﬁxed paraﬃn-embedded (FFPE) tissue
specimens. Laser microdissecting the cancer cells from the
pulmonary patient tissues is an eﬃcient way to make: (i)
drug-speciﬁc target discovery and (ii) biomarker discovery
studies. It allows for expert pathological identiﬁcation of the
tumor cells in the tissue compartments, which is made by
an electronic image analysis report. The areas within the
tissues are marked by the pathologist. Next, the operator
can use the marked image in order to make the laser micro-
dissection and tumor cell isolation. This strategy allows for
expert utility, where the experimental operators are distantly
separated geographically.
Biomarker diagnosis studies were undertaken on large
cell neuroendocrine carcinoma (LCNEC) patients, applying
laser-microdissected tumor cell isolates [31]. LCNEC is a
rather new lung cancer phenotype and has been categorized
into one of the subtypes of large-cell carcinoma (LCC) [32].
The LCNEC phenotype, thus, was demonstrated to develop
high-grade neuroendocrine tumors. Classifying the LCNEC
phenotype is highly challenging, and as of now, there is
no deﬁnite treatment for LCNEC patients. As LCNEC has
not been found to be highly amenable to chemotherapy, as
compared to small-cell lung carcinoma (SCLC), a diagnostic
test is needed in order to separate the LCNEC patients
from LC and SCLC. An additional complication is also
that currently there is no speciﬁc marker for LCNEC that
accurately identiﬁes the disease evolvement, which allows for
a targeted treatment strategy.
FFPE tissues have been archived in hospitals worldwide,
together with detailed clinical records, for example, disease
history, clinical examination results, drug response, and
adverse reaction of individual patients. Recently, emerg-
ing technology for FFPE tissue proteomics has made it
possible to study protein expression using FFPE tissue
specimens, providing a great opportunity for biomarker
discovery using clinically archived FFPE tissues accompanied
by both deﬁnitive diagnoses and known clinical outcomes6 International Journal of Proteomics
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Figure 4: Mass spectra on the sequence identity of (a) Stathmin and (b) major vault protein (MVP) that was found diﬀerentially regulated
in the LCNEC patient tissues.
[18, 19, 28, 33–35].Ourproteomicstudiesutilizingthelaser-
microdissected FFPE tissues of LCNEC, LCC and SCLC,
resulted in more than 100 signiﬁcant protein biomarker
candidates [28]. Lately, MRM multiplex assay has become
popular due to their generic applicability [36, 37]. The
MS-based veriﬁcation study of these candidates has been
conducted by recent developments using MRM quantitative
mass spectrometry as a novel methodology [29].
Following validation of biomarkers, MRM oﬀers quan-
tiﬁcations of proteins in complex biological matrices where
key protein sequences are targeted within the assay [38]. In
combinationwithappropriatestableisotope-labeledinternal
standards, the MRM assay technology provides absolute
quantitation of the biomarkers. A great advantage is that
a high number of proteins of interest can be monitored
simultaneously within the MRM assay cycle.
MRM quantiﬁcations present high sensitivity and speed,
whichisafuturerequirement.High-throughputscreeningof
clinical samples for candidate biomarkers within the clinical
study area is the next frontier, where the MRM technology is
developing further.
Our MS-based quantitative studies of those candidates
have veriﬁed 44 promising biomarker candidates, using
MRM [28]. Figure 4 shows the corresponding MS/MS spec-
tra of (a) Stathmin and (b) major vault protein (MVP) from
the corresponding MRM quantitation readouts. We discov-
ered that Stathmin is highly expressed in neuroendocrine
lung tumors (within the SCLC and LCNEC patient groups),
and that MVP would be signiﬁcant to LCC [18, 19]. It is
expected that their subset of candidates would be useful for
an improved diﬀerential diagnosis of LCNEC patients. These
studies are undertaken by our research team as well as others
throughout almost a decade. The studies undertaken in
Japan are all performed in a clinical environment with close
collaborationtotheexpertiseofhospitals. Thesurgeonshave
provided the bed-side resected tissue samples forour studies,
along with clinicians, that have been giving their experienced
guiding for bioﬂuid sampling, CT-imaging, and clinical
demography data. In addition, we have been collaborating
closely with pathologists who have performed the diagnosis
o fp a t i e n t sa n db e e ni n s t r u m e n t a li no u ro w np r o t e o m i c
studies,whencomparingclassicalhistologywithproteomics-
generated biomarker diagnosis predictions.
In view of this, the recently approved Neuroendocrine
Lung Cancer group, which in terms of diagnosis is a highly
challenging lung cancer phenotype to verify, will have novel
biomarker candidates, that has the opportunity to exchange
immunohistochemical identity of patients with protein
sequencing assay technology.
Histology still remains the standard for pathology
staging, used as a golden standard for protein biomarker
diagnosis and proteomics [39], why the validation of the dis-
covered biomarkers was run on additional LCNEC patients.
The corresponding immunohistochemical identities were
conﬁrmed in these histology studies, shown in Figure 5.
5. DrugLocalization in TissueCompartments
by Maldi DrugImaging
The basic understanding of the disease developments and
the pathophysiological landmarks that these changes leave
is the starting point for an understanding of the molecular
ﬁngerprint that these disease stages establish. In vivo disease
models developed for a given disease state, or rather a
mimic of a patient group biology occurrence, are currently
a rapidly growing research area. The translation from in vivo
animal disease models and the predictive values in a human
clinical study setting is a critical phase of drug development,
establishing the patient dose levels.
Drug localization after administration is highly valu-
able clinical information, where both target speciﬁcity andInternational Journal of Proteomics 7
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Figure 5: Immunohistochemical staining of LCNEC tissue for (a) Stathmin and (b) for major vault protein (MVP).
redundancy can be determined. An understanding of the
pharmacokinetic as well as pharmacodynamic properties of
a drug is of mandatory importance in drug development
processes. Imaging technologies are gaining more power in
drug characterization, utilizing positron emission tomogra-
phy (PET), MRI, MS-CT, and MALDI imaging. In order
to increase the basic knowledge about drug substances
and their pharmacological eﬀects, MALDI-imaging model-
based developments have been introduced lately, which
includes cell based as well as tissue-based validations of drug
compounds [40]. The distribution of TARCEVA in tumor
tissues isolated from a lung cancer patient is illustrated in
Figure 6.
6. Conclusions
Itisenvisionedthattheupcominggenerationofpersonalized
drugs for targeted and stratiﬁed patient treatment will break
through in major disease areas such as lifestyle-related
cancers, in particular lung cancers that have the highest
mortality including a predisposing disorder chronic obstruc-
tive pulmonary disease. Other cancers such as, for instance;
breast, colon, malignant melanoma, and brain are expected
to have targeted treatments in the coming years. In addition,
cardiovascular diseases, neurodegenerative diseases such as
multiple sclerosis (MSc), Parkinson, and Alzheimer, obesity,
and diabetes are additional disease areas where a multitude
of pipeline drugs are expected to make it as products
into the market, and the shelves of the local pharmacy,
readily available for patients. Mass spectrometric technolo-
gies can provide the “phenotypic ﬁngerprint” required for
the concept of personalized medicine. Mass-spectrometry-
driven target biomarker diagnoses in combination with
high-resolution computed tomography can provide a critical
pathway initiative facilitated by a fully integrated e-Health
infrastructure system.
ExpertCommentary
Targeted drugs, as the new generation of medicines, are
expected to be used in combination with diagnostics, in
ordertoincreaseeﬃcienttreatmentofpatients.Itisalsotobe
expected that the strong increase in biomarker developments
will play a signiﬁcant role in these strategic changes that will
be of huge beneﬁts to the health care as well as to the society
and taxpayers. With technology developments associated to
the personalized treatment, the clinical chemistry unit of
future hospitals will also be making an increased number
of analysis and assays in order to provide stronger diagnosis
basis for the doctors at hospitals to make improved disease
diagnosis of the patient.
We will also see a fast development of higher throughput
diagnostic assays, where the breakthrough of the human
genome and the human proteome will be used as the basis
for these developments.
AF i v e - Y earV ie w
We do expect that during a ﬁve-year period we have
reached a point where protein-based biopharmaceuticals
or biologicals have taken a larger percentage of the drug
market with a targeted drug approach. Improved clinical
chemistry diagnosis with gene- and protein-sequence-based
assays will also become state of the art in future medical
health care that will result in a much higher number
of overall measuring points. High-throughput multiplexed
biomarker assay platforms will play an important clinical
role as becoming a complement to traditional immunoassays
for future use in clinical health care and targeted medicine.
The introduction of new biomarkers of tumors, emphysema,
and inﬂammatory reaction in the lung will assist in early
identiﬁcation of disease and in monitoring the eﬀect of
therapeutic agents on disease progression.
Key Issues
(i) Within lung cancer, there have been reports on early
indication of somatic mutation appearances within
the EGF receptor, where personalized drugs in Japan
h v eb e e np r o v e nh i g h l ye ﬃcient.
(ii) Personalized medicine is more cost-eﬀective for
society, with an overall beneﬁt for the patients as well
as for the tax payers.8 International Journal of Proteomics
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Figure 6: Enlarged region of a squamous cell lung tumor section with MALDI-MS read out of the Erlotinib fragment ion (m/z 336.19) and
HE stained histological details. Typical areas of tumor cells are indicated with yellow-dashed lines.
(iii) Japan has declared a pricing strategy that includes
request for new biomarker diagnostics that can be
used for patient stratiﬁcation.
(iv) Wewillalsoseeafastdevelopmentofhigherthrough-
put diagnostic assays, where this breakthrough will
become a new milestone in modern healthcare.
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